Contrarian picks that promise big profits

Alec Cutler of Orbis Global Balanced Fund finds three stocks ripe with opportunity.

Each week, a professional investor tells us where he'd put his money. This week: Alec Cutler of Orbis GlobalBalanced Fund finds three stocks ripe with opportunity.

Buying cheap stocks and holding onto them for a very long time is a winning investment strategy. While this may sound obvious, investors aren't stupid and cheap stocks are often cheap for a reason.This is the challenge for contrarian investors. In times of extreme negativity, a company might appear uninvestable at any price. Take a closer look, however,and there may be an opportunity investors have missed.

A transformed oil major

The result? BP is now growing production with lower spending, and the barrels from new projects are more profitable than the barrels they replace, resulting in much higher free cash flow. Yet the stock is still priced at a near-6% dividend yield and 14 times consensus earnings for 2019, reflecting ongoing pessimism about the industry.

Take a long-term view of AbbVie

While this blockbuster drug drives considerable earnings and cash flow for AbbVie, the market is concerned about how AbbVie will grow once it loses US patent protection on Humira in 2023. Instead of maximising sales of Humira through to 2023, AbbVie will intentionally cannibalise Humira revenue with its two new drugs, which are proving to be more effective than Humira.

We believe that cannibalising in return for longer patent protection is the right strategy for the long term, but realise that this is likely to make for a bumpy ride in the short to medium term. We are happy to wait. At less than ten times our 2019 earnings estimate and a yield of 5.3%, AbbVie currently has one of the lowest valuations and highest yields in the sector, despite industry-leading earnings growth and one of the most active and promising late-stage drug pipelines.

Investors ignore Bayer's benefits

In addition, the seed business has profited from decades of investment and research into product development, which have made it very difficult for rivals to gain a foothold. Bayer also has a high-quality pharmaceutical business; at eight times consensus earnings for 2019 for the company overall, the market is clearly ignoring that too.

Indeed, we believe the market is overestimating the costs of the Roundup affair. The current price implies the settlement would be more than £700,000 per plaintiff, which is well above the pay-outs for similar suits in the past, and in our opinion highly unlikely.

Recommended

Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
19 Feb 2021
Four investment trusts for income investors to buy now
Investment trusts

Four investment trusts for income investors to buy now

Some high-yielding listed lending funds have come through the crisis with flying colours. David Stevenson picks four of the best.
12 Apr 2021
Three of corporate Japan’s hidden gems to buy now
Share tips

Three of corporate Japan’s hidden gems to buy now

Professional investor Nicholas Price of the Fidelity Japan Trust picks three of his favourite Japanese stocks that he thinks the market has overlooke…
12 Apr 2021
Share tips of the week
Share tips

Share tips of the week

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
9 Apr 2021

Most Popular

The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021
Four investment trusts for income investors to buy now
Investment trusts

Four investment trusts for income investors to buy now

Some high-yielding listed lending funds have come through the crisis with flying colours. David Stevenson picks four of the best.
12 Apr 2021
Central banks are rushing to build digital currencies. What are they, and what do they mean for you?
Bitcoin

Central banks are rushing to build digital currencies. What are they, and what do they mean for you?

As bitcoin continues to soar in value, many of the world’s central banks are looking to emulate it by issuing their own digital currencies. But centra…
8 Apr 2021